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Abstract
Background—Studies of ≤15 atrial fibrillation (AF) patients have identified atrial-specific 
mutations within connexin genes, suggesting that somatic mutations may account for sporadic 
cases of the arrhythmia. We sought to identify atrial somatic mutations among patients with and 
without AF using targeted deep next-generation sequencing of 560 genes, including genetic 
culprits implicated in AF, the Mendelian cardiomyopathies and channelopathies, and all ion 
channels within the genome.
Methods and Results—Targeted gene capture and next generation sequencing were performed 
on DNA from lymphocytes and left atrial appendages of 34 patients (25 with AF). Twenty AF 
patients had undergone cardiac surgery exclusively for pulmonary vein isolation, and 17 had no 
structural heart disease. Sequence alignment and variant calling were performed for each atrial-
lymphocyte pair using the Burrows-Wheeler Aligner, the Genome Analysis Toolkit, and MuTect 
packages. Next generation sequencing yielded a median 265-fold coverage depth (IQR 164–369). 
Comparison of the 3 million base pairs from each atrial-lymphocyte pair revealed a single 
potential somatic missense mutation in 3 AF patients and 2 in a single control (12 vs. 11%; p=1). 
All potential discordant variants had low allelic fractions (range: 2.3–7.3%) and none were 
detected with conventional sequencing.
Conclusions—Using high-depth next generation sequencing and state-of-the art somatic 
mutation calling approaches, no pathogenic atrial somatic mutations could be confirmed among 25 
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AF patients in a comprehensive cardiac arrhythmia genetic panel. These findings indicate that 
atrial specific mutations are rare and that somatic mosaicism is unlikely to exert a prominent role 
in AF pathogenesis.
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Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and affected 
patients suffer from an increased risk of heart failure, stroke, and death.1,2 Despite its 
clinical importance, current treatment strategies for the arrhythmia, including both anti-
arrhythmic drugs and catheter ablation, have relatively modest long term efficacy.3,4 The 
lack of definitive therapies for AF likely stems from a limited understanding of its 
underlying pathophysiology, emphasizing a need for novel insights.5 Recent work has 
increasingly highlighted a genetic contribution to the arrhythmia, especially when AF occurs 
in the absence of structural heart disease.6–14
Although a positive family history of the arrhythmia is a major risk factor for AF in the 
absence of overt cardiovascular disease,15 a substantial proportion of cases are sporadic.16 
Given that these cases develop in the absence of identifiable risk factors, it is still probable 
that genetics play a role. The apparent lack of family history may be secondary to complex 
polygenic interactions that may lead to correspondingly complex patterns of inheritance. An 
alternative mechanism accounting for these sporadic cases may be de novo mutations 
occurring within germline or somatic cells that give rise to the atria.
A somatic mutation that develops within a myocardial progenitor cell will be absent from 
peripheral lymphocytes, precluding its detection on routine genetic testing. The resultant 
cardiac “mosaicism”, referring to the mutation being confined to a proportion of cells in the 
heart, has the potential to result in regional electrical heterogeneity within the atria that 
could serve as an ideal substrate for the initiation and maintenance of AF.17 Guided by this 
concept, investigators identified somatic mutations within connexin genes, the molecular 
constituents of gap junctions, in early onset, sporadic AF patients (n=15 and n=10) who had 
no evidence of structural heart disease or AF risk factors.18,19 Given the high yield of 
screening, the investigators hypothesized that cardiac mosaicism may be a common cause of 
sporadic AF within structurally normal hearts.
The advent of next-generation sequencing has revolutionized cancer diagnostics, a condition 
whose underlying pathophysiology is largely driven by somatic mutations.20 Through the 
ability to rapidly screen large numbers of genes in a cost-effective manner, next-generation 
sequencing has led to the identification of novel genetic culprits and has improved insight 
into the burden of somatic mutations within tumors.21 Equally as important and in parallel 
with these technological advances, increasingly sophisticated probabilistic variant calling 
approaches have been developed to maximize sensitivity and specificity of detected variants. 
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We sought to extend the use of these advances to the heart in order to evaluate the burden of 
atrial somatic mutations and investigate their potential impact on AF.
Methods
Study Population
Consecutive consenting adult patients ≥ 18 years old undergoing cardiac surgery with left 
atrial appendage excision at Sutter Hospital, Sacramento Medical Center were recruited 
between October 1, 2010 and November 1, 2012. Patients were excluded if they had 
congenital heart disease, any history of rheumatic valve disease or mitral stenosis, if a right 
thoracotomy approach was employed, if they were unable to provide informed and 
witnessed signed consent, or if they were pregnant or incarcerated. Participant demographics 
and medical details were obtained using a study questionnaire and were verified with a 
subsequent chart review. All study participants provided informed written consent under 
protocols that were approved by the University of California, San Francisco (UCSF) and 
Sutter Hospital, Sacramento, CA.
Custom Targeted Genetic Panel
The genetic panel was designed in order to include all ion channels within the genome and 
genes previously implicated in Mendelian forms of cardiac disease as of November, 2013. 
The list of ion channels was constructed through a search of the Uniprot Knowledgebase 
using the terms ion channel and human. The 502 candidates were further manually curated 
to verify that the listed gene encoded an ion channel. This strategy led to the identification of 
398 separate genes that were incorporated into the genetic panel (Data Supplement, Table 
1).
An additional 162 genes were selected based on their documented or potential involvement 
in primary cardiac disease (Data Supplement, Table 1). We constructed this aspect of the 
genetic panel through a review of the genetic culprits associated with the following 
conditions: Long QT syndrome, Short QT syndrome, Brugada syndrome, Catecholaminergic 
Polymorphic Ventricular Tachycardia, Early Repolarization Syndrome, Idiopathic 
Ventricular Fibrillation, Arrhythmogenic Right Ventricular Cardiomyopathy, Hypertrophic 
Cardiomyopathy, Dilated Cardiomyopathy, Restrictive Cardiomyopathy, Left Ventricular 
Non-Compaction, and Mitochondrial Cardiomyopathy. In addition, we included all genes 
implicated by proxy in the pathogenesis of AF from genome wide association studies and 
other genes whose protein products have been implicated in the pathophysiology of the 
arrhythmia.
We extracted all known exons of the 560 genes using the Ensembl General Transfer Format 
(gtf) file annotating all transcripts in the human genome (release 68). In order to obtain 
exhaustive coverage of protein coding regions of genes of interest, a customized set of 
hybridization probes was designed and constructed using the Nimblegen SeqCap EZ Library 
kit (Roche NimbleGen, Madison, WI). In total, 3,218,095 of the 3,330,918 bases of interest 
were covered by one or more probes.
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DNA and Library Preparation
Intraoperatively, left atrial appendage samples were immediately flash frozen in liquid 
nitrogen in a sterile fashion. Genomic DNA was isolated from atrial tissue using the AllPrep 
DNA/RNA Mini Kit (Qiagen, Valencia, CA). Matching lymphocyte DNA was purified from 
the buffy coat using the GentraPuregene Blood Kit (Qiagen) obtained from phlebotomy 
performed prior to surgery.
In order to generate sequencing libraries, 1 microgram of DNA from each sample was 
randomly sheared to approximately 200 base pairs using a Covaris S2 Ultrasonicator 
(Covaris, Woburn, MA). Subsequent library preparation was performed using the KAPA 
Library Preparation Kit (Kapa Biosystems, Wilmington, MA). Briefly, genomic DNA 
fragments were end-repaired and underwent A-tailing prior to adaptor ligation with 24 
unique NEXTflex DNA Barcodes (Bioo Scientific, Austin, TX). Library enrichment was 
then performed through polymerase chain reaction (PCR) amplification, followed by 
analysis of the size and quantity of ligated fragments using the Agilent 2100 Bioanalyzer 
(Santa Clara, CA). Recommended clean-up was performed at each step using Agencourt 
AMPure XP Beads (Beckman Coulter, Indianapolis, IN).
Targeted Gene Capture & Sequencing
The barcoded DNA library for each sample was then pooled with equal quantities of 23 
other unique barcoded libraries to a total of 1 microgram. The corresponding 24 NEXTflex 
DNA Barcode Blockers and COT human DNA were added to each pooled sample and then 
heat dried using a DNA vacuum concentrator. Hybridization of the genomic libraries with 
the custom designed genetic panel was then performed consistent with manufacturer 
specifications.
Following hybridization, the targeted fragments were pulled down and recovered using 
Streptavidin-coupled Dynabeads (Life Technologies, Grand Island, NY). Library enrichment 
and product analysis was repeated as detailed above. 101 base pair paired-end sequencing 
was performed on an Illumina HiSeq 2500 sequencer with 24 samples to each lane of a flow 
cell. Samples were demultiplexed prior to analysis.
Analysis
The Burrows-Wheeler Aligner (bwa) was used to align paired-end short reads to the human 
genome, while the Genome Analysis Toolkit (GATK) was used for local realignment and 
recalibration.22,23 Sequencing quality metrics, including number of mapped reads, number 
of duplicate reads, and number of mappable bases were performed with samtools, Picard 
tools, and GATK (Data Supplement, Figures 1 and 2).23,24 A total of 90 genes contained 
isolated base pair regions with inadequate coverage precluding reliable variant calling, 
collectively accounting for no more than 0.7% of the region of interest (Data Supplement, 
Figure 3).
As a quality assurance measure, we compared single nucleotide polymorphism (SNP) minor 
allele frequencies observed from our data with those from the 1000 Genomes CEU 
population.25 We identified 2369 SNPs within our coverage area with minor allele 
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frequency estimates of at least 5%. As inclusion of non-European individuals would 
generate inconsistent frequency estimates, we performed principal components analysis and 
removed 3 individuals based on the first principal component. Minor allele frequency 
estimates were generated using the remaining samples and plotted against 1000 Genomes 
CEU frequencies.
To improve variant calling, an estimate of cross-contamination of each sample was first 
obtained using the ContEst program (Data Supplement, Figure 4).26 Per sample estimates 
were then input into MuTect, allowing more accurate models for variant detection. MuTect 
is a state-of-the-art somatic mutation caller designed to maximize sensitivity and minimize 
the impact of technical sources of false positives.27 The software program uses a 
probabilistic model to call differences based on number of reads, mapping quality, strand 
bias, and estimates of cross-contamination. Importantly, “tumor” and “normal” sources are 
analyzed in parallel, preventing the false positives and negatives that typically arise from 
performing a post hoc comparison of variant files after variant calling has already been 
performed on the samples independently.
We applied the default MuTect parameters to identify potentially discordant variants 
between atrial and lymphocyte DNA. We observed that the overwhelming majority of 
variants that emerged from this analysis corresponded to G>T transversions (Data 
Supplement, Figure 5). Low level G>T transversions have become recognized as an 
important artifactual change that occurs with high coverage next-generation sequencing and 
are felt to arise secondary to oxidative damage that occurs during acoustic shearing of 
genomic DNA during sample preparation.28 This oxidative damage occurs regardless of 
DNA source (ie. tissue versus lymphocyte). Although not an issue for germ-line mutation 
calling due to their trace quantities not being consistent with a heterozygous state, their low 
levels may be confused with somatic mutations. As a result, the recommended bioinformatic 
approach to G>T transversions within the cancer literature has been to filter them from the 
analysis given the overwhelming probability that they represent sequence artifacts.28 
Consistent with this methodologic approach, we also elected to filter G>T transversions 
from our analysis in an effort to minimize false positive findings.
Among the final discordant atrial variants, SnpEff (v. 3.3) was used to assess their impact on 
protein coding sequence.29 Atrial-lymphocyte discordant variants expected to change 
protein sequence were further scrutinized with manual annotation, including examining their 
frequency in control populations, visualizing mapped reads, and analyzing whether the 
regions of interest map ambiguously in the genome. Discordant variants were also analyzed 
for their presence in multiple participants within the cohort and for evidence of occurrence 
in the “reverse direction” (absent in atrial cells and present within lymphocytes) among 
other members of the cohort; findings suggestive of systematic sequencing errors. A 
summary of our overall analytical approach to discordant variant calling is outlined in 
Figure 1. Somatic fractions, defined as the percentage of total reads within an atrial sample, 
were determined for each remaining discordant atrial variant.
Attempted verification of potential discordant variants was pursued with Sanger sequencing 
of atrial DNA from relevant study participants. Amplification of targeted genomic regions 
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was performed using polymerase chain reaction (primer sequences provided in the Data 
Supplement) followed by DNA sequencing using the ABI PRISM dye terminator method 
(Applied Biosystems, Foster City, CA, USA).
Somatic Mutation Rate
Because of the sensitivity of the sequencing employed, it is not possible to definitively 
distinguish potential false positive discordant variants that pass through our filtering 
protocol from actual somatic mutations with low somatic fractions. In order to obtain a 
conservative estimate, we based our calculations of somatic mutation rates on the 
assumption that all possible somatic mutations that passed our a priori filtering processes 
were real. These rates were calculated by dividing the total number of somatic mutations by 
the total number of nucleotides examined in both AF cases and controls. The mean somatic 
mutation rate was reported as the number of somatic mutations per 100 million nucleotides.
Statistical Analysis
Normally distributed continuous variables are presented as means ± standard deviation and 
the Student’s t-test. Comparison of categorical values was performed using the Chi-squared 
and Fisher’s Exact tests. SNP minor allele frequencies within our cohort and the 1000 
Genomes Project CEU subpopulation were compared using the Pearson pairwise correlation 
coefficient. In order to evaluate the possibility that filtering of G>T transversions may have 
resulted in a reduced sensitivity for detecting bona fide somatic mutations, we conducted a 
Monte Carlo simulation analysis to estimate the anticipated number of G>T transversions 
that would result in functional coding changes. Given that there are 12 nucleotide changes 
that could be observed for somatic mutations, with each assumed to be equally likely, we 
were able to generate a robust bootstrap estimate of the number of G > T changes expected 
under the assumption of no oxidative artifact. We used the total number of pre-filtered 
observed changes (synonymous and non-synonymous) as an empirical distribution and 
performed 10,000 random draws. For each draw and for each potential variant, we estimated 
a probability of missense mutation (using the observed missense rate and allowing some 
uncertainty) and totaled the result. A posterior mode and 95% credible interval were 
computed from the posterior distribution.
Two-tailed p-values < 0.05 were considered statistically significant. Statistical analyses were 
performed using Stata version 12 (College Station, Tx, USA) and R.
Results
Patient Characteristics
A total of 34 patients undergoing cardiac surgery with left atrial appendage excision at 
Sutter Hospital, Sacramento provided both atrial tissue and peripheral blood for sequencing 
analysis. Twenty-five had a history of AF, and 20 were undergoing cardiac surgery 
exclusively for a minimally invasive AF ablation. Among the participants with AF, the mean 
age at diagnosis was 63.0 ± 11.9 years and 16 (64%) were male. Seventeen participants had 
AF in the absence of structural heart disease, 13 of whom had no family history of the 
arrhythmia. There were 11 individuals with AF in the absence of all known AF risk factors 
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(including hypertension), 9 in the absence of a known family history. The remaining 
baseline characteristics of the participants are summarized in Table 1.
Next Generation Sequencing
Targeted gene capture and high-throughput sequencing permitted alignment of 16.5 million 
reads per sample (IQR 12.2–19.5 million) at a median 265-fold coverage depth (IQR 164–
369) (Figure 2). With respect to GJA1 and GJA5, the median fold-coverage depths were 267 
(IQR 171–422) and 234 (IQR 149–369), respectively. The median number of mapped bases 
per sample was 3.25 million (IQR 3.246–3.259 million), or 99.3% of the bases of interest. 
Comparison of the minor allele frequencies of 2369 SNPs from our cohort and the 1000 
Genomes Project CEU subpopulation revealed a strong correlation (rho = 0.96; Data 
Supplement, Figure 6).
Analysis and Filtering Steps
Bioinformatic analysis using the somatic mutation caller MuTect initially identified 8710 
discordant base calls when treating lymphocytes as the reference (“germline”) DNA source 
and atrial tissue as the somatic DNA source. Notably, 8604 (98.8%) of these discordant base 
calls represented G>T transversions, an aforementioned common source of artifactual DNA 
mutations arising secondary to oxidative damage during sample preparation.28 No G>T 
transversions resulting in non-synonymous missense mutations were observed within GJA1 
or GJA5. Selective filtering of false positive G>T transversions was precluded by the 
absence of previously reported contextual and strand bias. Monte Carlo simulation analysis 
revealed a 63% probability that none of the previously filtered G>T transversions reflected 
bona fide functional somatic mutations (95% CI: 0–2) (Data Supplement, Figure 7). 
Classification of G >T transversions as false positives reduced the list of discordant base 
calls to 106. From this list, an additional 5 were flagged by MuTect as having poor 
coverage, and thus reduced reliability for variant calling.
Potential Atrial Specific Variants
The above filters resulted in a total of 101 potential somatic atrial variants. A “reverse” 
analysis, treating atrial samples as reference and lymphocytes as the somatic tissue revealed 
a comparable number (93) of variants. Within the overall list, 12 represented non-
synonymous SNPs predicted to impact the protein coding regions of a total of 11 genes. The 
remaining discordant base calls represented synonymous SNPs or were located within 
intronic regions.
Of the 12 potential non-synonymous SNPs observed within atria and not in lymphocytes, an 
additional 7 were found to be consistent with sequencing artifact on the basis of their 1) 
being observed in multiple participants (a systematic error associated with the sequencing 
protocol was felt to be the likely explanation, particularly given that certain of these variants 
were present within highly repetitive regions of DNA prone to alignment errors); 2) being 
observed in the “reverse direction” (present within lymphocytes and absent from atrial cells) 
among other participants; 3) having a greater than 50% carrier frequency within the general 
population. The 5 remaining discordant genetic variants did not have population data 
frequency available indicating that they were either rare or novel (Table 2). The discordant 
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variants were carried by 3 of the 25 participants with AF and 2 were present within a single 
control participant with no prior history of the arrhythmia (12% vs. 11%, p=1).
Somatic Fractions and Sanger Sequencing
The somatic fractions, defined as the percentage of total reads within the relevant atrial 
sample, for the 5 remaining potential non-synonymous cardiac somatic mutations ranged 
from 2.3 to 7.3%. Sanger sequencing of atrial samples from each patient carrying a potential 
discordant variant yielded electropherograms with no evidence of a somatic mutation 
(Figure 3).
Somatic Mutation Rate
Among the 25 AF cases, there were 3 potential somatic mutations and an average of 3.25 
million mapped base pairs per sample corresponding to an average somatic mutation rate of 
4 per 100 million nucleotides (range: 0–31, standard deviation: 10). A total of 2 potential 
somatic mutations were observed among the 9 control participants, and the average mapped 
base pairs per sample was also 3.25 million. This yields an average somatic mutation rate 
among controls of 7 per 100 million (range: 0–62, standard deviation:21).
Discussion
Our next-generation sequencing study targeting 560 genes found no evidence to support a 
role for somatic mosaicism in the pathogenesis of AF among 25 affected patients (17 with 
no structural heart disease and 11 with no AF risk factors including hypertension) and 9 
control participants. Our study screening for atrial somatic mutations is the largest to date 
and is the first to assess a large number of genes. We found no missense somatic mutations 
within the GJA5 and GJA1 genes and no difference in the frequency of potential somatic 
mutations between AF cases and controls within our cohort (12% vs. 11%, p=1). Our 
findings also suggest that atrial somatic mutations are rare, further reinforcing the notion 
that atrial mosaicism exerts a minimal role in AF pathogenesis.
Our findings contrast with previous work suggesting that approximately 20% of non-familial 
AF occurring in the absence of structural heart disease may be secondary to somatic 
mutations within GJA5 and GJA1, encoding connexin 40 and 43, respectively.18,19 Given a 
nearly 20% yield from screening just two genes, it was reasonable to speculate that somatic 
mosaicism may reflect a common underlying pathophysiology in AF with important clinical 
implications. In addition to failing to detect any evidence of somatic mutations within either 
GJA5 or GJA1, the overall somatic mutation rate among AF cases in our study was also very 
low (4 per 100 million nucleotides). We found only 3 discordant atrial-lymphocyte genetic 
variants projected to result in functional changes and each had a very low atrial somatic 
fraction. Notably, none could be confirmed by traditional Sanger sequencing. Indeed, even if 
“real”, it is unclear if such low somatic fractions (from 2.3–7.3%) would have any 
meaningful clinical relevance. These findings argue that atrial mosaicism is unlikely to exert 
a prominent role in AF pathophysiology.
There are two possible explanations for the contrasting results between the current and 
previous studies, namely patient selection and sequencing artifact secondary to formalin 
Roberts et al. Page 8













fixation. In both previous connexin studies, the investigators restricted their cohort to 
individuals with early onset (age<55), sporadic AF.18,19 The mean age at AF diagnosis in 
the GJA5 study was 45.1 ± 5.9 years and patients were free of co-morbidities, while our AF 
cohort was older (63.0 ± 11.9 years), approximately 50% had hypertension, and 7 of the 25 
study participants with AF had an affected family member. It is conceivable that the 
selection criteria for the previous cohorts may have resulted in patients that had a higher 
burden of atrial specific mutations within cardiac genes.
Patient selection alone, however, is unlikely to account for our discordant findings in 
relation to the prior AF somatic mutation reports. The previously reported high rate of atrial 
somatic mutations was likely impacted by PCR artifacts following DNA extraction from 
formalin-fixed paraffin-embedded tissue.30 A growing number of papers within the 
oncology literature have warned about the potential for erroneously identifying somatic 
mutations in tumor samples previously fixed with formalin.30–33 Within the field of 
cardiology, initial reports suggesting that NKX2-5 somatic mutations were a common cause 
of congenital heart disease were subsequently shown to likely reflect false positives 
secondary to formalin-fixation.34–36 Of note, our atrial DNA samples were obtained from 
tissue that was flash-frozen immediately after excision, whereas the previous connexin 
mutations were identified following DNA extraction from formalin-fixed and paraffin-
embedded left atrial appendage tissue.18,19 Despite the apparent overestimation of the role 
of atrial specific connexin mutations in AF, it should be noted that the reported atrial 
somatic GJA1 mutation has also been reported as a somatic mutation from a flash-frozen 
gastrointestinal tumor source.37 It is also important to emphasize that these somatic 
mutations were described alongside the first connexin germline mutation associated with 
AF, findings subsequently substantiated by the role of rare connexin 40 mutations in familial 
AF.38,39
Although it is conceivable that our bioinformatic methods for detecting somatic mutations 
with next-generation sequencing may have underestimated their true prevalence, it should be 
noted that the approach utilized has been extensively validated and shown to have extremely 
high sensitivity and specificity.20,40,41 At our median sequencing depth (265-fold), the 
estimated sensitivity for detecting somatic mutations with an atrial somatic fraction of 10% 
is 99.999%. When the atrial somatic fraction drops to 5%, 2%, and 1%, our sensitivity for 
detection correspondingly falls to 99.2%, 76.8%, and 26.9%, respectively.27 These 
sensitivity estimates far exceed those for Sanger sequencing, the approach utilized for 
identifying the previous somatic mutations in AF patients. The atrial somatic fractions for 
the previously documented GJA5 and GJA1 somatic mutations implicated in AF were 
estimated to range from 20 to 34% based on the results of allelic subcloning.18,19 Given our 
anticipated sensitivity, it is very unlikely that we failed to detect somatic mutations with 
atrial somatic fractions in that range.
The challenges of recognizing artifactual mutations in previous small scale studies 
highlights one of the main strengths of our study – the analysis of an unprecedented number 
of bases within multiple genes across multiple affected and control individuals. Focus on a 
small number of genes or samples would have failed to detect systematic biases, such as the 
G>T oxidative changes, or sample cross-contamination, and these would have been 
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erroneously interpreted as somatic mutations. Additionally, the availability of control 
samples allowed filtering of recurrent artifactual mutations that likely arise from alignment 
errors. In fact, the somatic mutation calling pipeline of most large tumor sequencing centers 
includes a critical filtering step whereby all variants previously observed in a large panel of 
hundreds of control samples are removed, as these are likely to represent artifact arising 
from one or more steps in the variant calling process.42
The absence of evidence to support a role for atrial somatic mutations in AF within our 
cohort should not be viewed as evidence to completely rule out somatic mosaicism as a 
pathophysiological mediator of AF. Although our results suggest that such a mechanism is 
likely rare, at least one other study identified a potential disease-causing somatic mutation in 
an arrhythmic disease.43 However our results suggest that the vast majority of cases of 
sporadic, AF occurring in the absence of overt cardiovascular disease develop secondary to 
either another genetic mechanism or some as yet unknown exposure. Because this form of 
AF accounts for up to 30% of all AF cases and the majority appear to be sporadic, these 
patients comprise a substantial number in the population.16,44 Furthermore, because 
understanding the etiology of the disease in these individuals should uncover mechanisms 
unique to AF itself (rather than simply an AF risk factor, such as congestive heart failure), it 
is critical to assure that research efforts are on the right track. Therefore, although our results 
are “negative”, we believe this comprehensive investigation is sufficiently robust to steer the 
field towards examining novel polygenic or gene-environment interactions, as well as 
potential behaviors or environmental influences that may be important.
Limitations
Although our study examining for atrial somatic mutations involves both the largest number 
of patients and genes tested to date, our cohort size of 25 AF patients and 9 controls is still 
modest. In addition, our bioinformatic methods for identifying somatic mutations with next-
generation sequencing, although highly sensitive and state-of-the-art, could potentially have 
failed to identify bona fide atrial somatic mutations (particularly those with an atrial somatic 
fraction ≤2% when our sensitivity is estimated to drop below 95% given our median 265-
fold coverage depth). Although the frequency of potential somatic mutations was similar in 
both cases and controls, we cannot exclude the possibility that the discordant variants among 
the AF cases were pathogenic while those in controls were benign. Finally, although our 
genetic panel covered more than 3 million base pairs and an exhaustive number of genes 
related to cardiac pathophysiology (including the genes previously implicated in somatic 
mutations), it remains possible that genetic mosaicism involving undiscovered variants 
related to AF could yet be important. We chose to restrict our analysis to 560 genes in order 
to assure high depth coverage, thereby maximizing our sensitivity and specificity for 
accurately identifying somatic mutations.
Conclusions
Using high-depth next generation sequencing and state-of-the art somatic mutation 
identification approaches, we found no evidence to support a role for pathogenic atrial 
somatic mutations in AF using a comprehensive cardiac genetic arrhythmia panel. These 
Roberts et al. Page 10













findings indicate that atrial specific mutations are rare and suggest that somatic mosaicism 
likely exerts a minimal role in the pathogenesis of AF.
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Sequencing Coverage Depth Among Atrial and Lymphocyte Samples. Boxes represent 25th 
to 75th quartiles and lines within boxes represent median values. Outliers are displayed by 
distinct dots.
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Possible Low Level Somatic Variants Identified with Next-Generation Sequencing Failed 
Detection with Sanger Sequencing.
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Table 1




n= 9 p value
Age (years) 64.2 ± 12.0 78.4 ± 8.2 0.003
Male 16 (64.0) 6 (66.7) 0.886
White Race 24 (96.0) 8 (88.9) 0.380
Hypertension 13 (52.0) 6 (66.7) 0.447
Diabetes Mellitus 5 (20.0) 1 (11.1) 0.549
Coronary Artery Disease 5 (20.0) 4 (44.4) 0.154
Congestive Heart Failure 3 (12.0) 1 (11.1) 0.943
Indication For Surgery
 AF Ablation 20 (80.0) 0 (0) <0.001
 Coronary Artery Bypass Grafting 2 (8.0) 4 (44.4) 0.014
 Aortic Valve Replacement 1 (4.0) 4 (44.4) 0.003
 Mitral Valve Surgery 2 (8.0) 2 (22.2) 0.256
Data are n (%) or mean ± standard deviation
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Table 2
Possible Discordant Non-Synonymous Atrial/Lymphocyte Genetic Variants
Genomic Position Gene Nucleotide Change Amino Acid Change Atrial Somatic Fraction
chr1:27440338 SLC9A1 C > A L264F 0.073
chr2:96781756 ADRA2B* C > A A45S 0.044
chr2:166894395 SCN1A* C > A R918L 0.029
chr15:78921890 CHRNB4 C > A V253F 0.030
chrX:152826150 ATP2B3 C > A D938E 0.023
*
ADRA2B and SCN1A were both identified in a single control participant. 3 different study participants with atrial fibrillation carried the remaining 
3 potential discordant variants.
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